<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161489">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01968395</url>
  </required_header>
  <id_info>
    <org_study_id>E2013_PK_CASPO70_LIVERFAILURE</org_study_id>
    <nct_id>NCT01968395</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure</brief_title>
  <official_title>Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to conduct a population pharmacokinetic analysis of
      caspofungin in a population of patients with moderate and severe acute alcoholic hepatitis
      or liver disease with Child-Pugh score B and C in order to better characterize
      pharmacokinetic parameters in case of moderate and severe liver dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      patients admitted for alcoholic hepatitis or decompensated cirrhosis and Child-Pugh score
      7-9 and 10-15 will be included; all patients without invasive aspergillosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Measurement of serum caspofungine concentrations to determine the pharmacokinetic parameters of Caspofungin in patients with liver failure</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>one dose of caspofungin will be given to patients with hepatic failure. Serum sampling will be performed during 96 hours. Measurements of caspofungin in the serum will be performed to study the pharmacokinetics of this drugs and will be compared with pharmacokinetics of subjects with normal liver function. For safety, patients will be followed during 14 days.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bacterial Infections and Mycoses</condition>
  <condition>Liver Disease</condition>
  <arm_group>
    <arm_group_label>Caspofungin 70 mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Infusion of one dose of Caspofungin 70 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caspofungin 70 mg</intervention_name>
    <description>Intravenous use</description>
    <arm_group_label>Caspofungin 70 mg</arm_group_label>
    <other_name>Cancidas</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver failure Child-Pugh B and C

        Exclusion Criteria:

          -  Cachexia (BMI &lt; 15 kg/m²)

          -  Pregnancy

          -  HIV

          -  Hepatitis C patients
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédérique JACOBS, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasme University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frédérique JACOBS, MD, PhD</last_name>
    <phone>+3225553111</phone>
    <phone_ext>4433</phone_ext>
    <email>frederique.jacobs@erasme.ulb.ac.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rudy SURIN, SCo</last_name>
    <phone>+3225553111</phone>
    <phone_ext>5807</phone_ext>
    <email>rudy.surin@erasme.ulb.ac.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erasme University Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique JACOBS, MD, PhD</last_name>
      <phone>+3225553111</phone>
      <phone_ext>4433</phone_ext>
      <email>frederique.jacobs@erasme.ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Frédérique JACOBS, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 23, 2013</lastchanged_date>
  <firstreceived_date>September 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Caspofungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
